| Overview |
| bs-5786R-A350 |
| KLST Polyclonal Antibody, ALEXA FLUOR® 350 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat |
| Specifications |
| ALEXA FLUOR® 350 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human KLST/Kallistatin (161-220aa) |
| 151-250/427 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5267 |
| Secreted |
| Serpin peptidase inhibitor clade A member 4; Kallikrein binding protein; Kallikrein inhibitor; Protease inhibitor 4; Serpin A4; KAL; Kallikrein binding protein; Kallikrein inhibitor; KBP; KLST; KST; MGC108582; PI4; Protease inhibitor 4; Serpin A4; Serpin peptidase inhibitor clade A member 4; SERPINA4; KAIN_HUMAN. |
| Kallistatin is a serine proteinase inhibitor which binds to tissue kallikrein and inhibits its amidolytic and kininogenase activity. Inhibition is achieved by formation of an equimolar, heat- and SDS-stable complex between the inhibitor and the enzyme, and generation of a small C-terminal fragment of the inhibitor due to cleavage at the reactive site by tissue kallikrein. Heparin blocks kallistatin's complex formation with tissue kallikrein and abolishes its inhibitory effect on tissue kallikrein's activity. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz